Corporate Symposia

Thursday, April 20


A Persistent Threat: VTE risk in Acute Medically Ill Patients and the Need for Extended Prophylaxis
Thursday, April , 20
6:00 PM - 9:00 PM
Gold 2

Hosted by Portola Pharmaceuticals

Dr Alpesh Amin will discuss Venous Thromboembolism (VTE) Prophylaxis and the unmet need in acutely ill medical patients after hospital discharge.
Alpesh N Amin, MD, MBA
Professor, Medicine
University of California Irvine School of Medicine
Chair, Department of Medicine
Executive Director, Hospitalist Program

The program will be seated on a first-come, first served basis and a plated dinner will be provided.
Click here and use Invitation code: LTR4WL to preregister and RSVP for the program.

Friday, April 21


Warfarin Management in the age of DOACs – the role of Point of Care PT/INR and Patient Self Testing
Friday, April, 21
12:30 PM - 1:45 PM
Gold 2

Hosted by Roche Point of Care

Program: When are DOACs not the answer for your patients? How can a systematic approach to in-office and in-home PT/INR testing help you to optimize your anticoagulation program?
Dr. Alan Jacobson will present clinical scenarios where Warfarin is still the appropriate anticoagulant therapy of choice. He will share clinical data and outline the benefits of in-office/clinic and patient-self testing options within the context of Systematic Anticoagulation Management.
A plated lunch will be provided.
Alan Jacobson, MD, FACC
Loma Linda University School of Medicine
Associate Chief of Staff/ Research
Director, Anticoagulation Services
Jerry L. Pettis VA Medical Center
Loma Linda, California

Click here for more information about the symposium.

We have had an overwhelming response to our luncheon and currently, all seats have been filled. Click here to be placed on our wait list. We anticipate seats will open up as we get closer to the event. You will be notified if we have additional availability, or you can stop by our Roche booth to get an update.

Thrombosis: AFib & DVT/PE An Exploration In Risk Reduction

Friday, April, 21
12:30 PM - 1:45 PM
Gold 3

Hosted by Janssen Pharmaceuticals, Inc.
This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism and how they can reduce the risk of recurrent thrombotic events. It will also present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.
Samuel A. Berkman, MD, FACP
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

The program will be seated on a first-come, first served basis and a plated lunch will be provided.